OKYO Pharma to Present OK-101 Phase 2 Dry Eye Data
Ticker: OKYO · Form: 6-K · Filed: Apr 2, 2024 · CIK: 1849296
Sentiment: neutral
Topics: clinical-trial-data, biotech, presentation
TL;DR
OKYO Pharma presenting OK-101 Phase 2 dry eye data at ASCRS partner meeting April 4th.
AI Summary
OKYO Pharma Ltd announced on April 2, 2024, that it will present Phase 2 data for its dry eye disease treatment, OK-101, at Eyecelerator 2024. This event is a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, scheduled for April 4, 2024.
Why It Matters
The presentation of Phase 2 data for OK-101 is a crucial step in the drug development process, potentially impacting OKYO Pharma's valuation and future clinical trial plans.
Risk Assessment
Risk Level: medium — The outcome of the Phase 2 data presentation could significantly influence investor sentiment and the company's stock price.
Key Players & Entities
- OKYO Pharma Ltd (company) — Registrant
- OK-101 (drug) — Treatment for dry eye disease
- Eyecelerator 2024 (event) — Presentation venue
- American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (event) — Associated meeting
- April 2, 2024 (date) — Announcement date
- April 4, 2024 (date) — Presentation date
FAQ
What specific Phase 2 data for OK-101 will be presented?
The filing does not specify the exact details of the Phase 2 data to be presented, only that it pertains to dry eye disease.
What is the significance of Eyecelerator 2024?
Eyecelerator 2024 is described as a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.
When was this Form 6-K filed?
This Form 6-K was filed on April 2, 2024.
What is OKYO Pharma's primary business?
OKYO Pharma Ltd is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
Where is OKYO Pharma's principal executive office located?
OKYO Pharma's principal executive office is located at 9th Floor, 107 Cheapside, London EC2V 6DN.
Filing Stats: 355 words · 1 min read · ~1 pages · Grade level 15.2 · Accepted 2024-04-02 07:00:07
Filing Documents
- form6-k.htm (6-K) — 27KB
- ex99-1.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 12KB
- 0001493152-24-012632.txt ( ) — 57KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: April 2, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 Press Release, dated April 2, 2024 4